CN117881664A - 作为nav1.8抑制剂的环烷基3-氧代哌嗪甲酰胺和环杂烷基3-氧代哌嗪甲酰胺 - Google Patents
作为nav1.8抑制剂的环烷基3-氧代哌嗪甲酰胺和环杂烷基3-氧代哌嗪甲酰胺 Download PDFInfo
- Publication number
- CN117881664A CN117881664A CN202280048071.1A CN202280048071A CN117881664A CN 117881664 A CN117881664 A CN 117881664A CN 202280048071 A CN202280048071 A CN 202280048071A CN 117881664 A CN117881664 A CN 117881664A
- Authority
- CN
- China
- Prior art keywords
- group
- alkyl
- methyl
- carboxamide
- oxopiperazine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
- C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Rheumatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163185637P | 2021-05-07 | 2021-05-07 | |
| US63/185,637 | 2021-05-07 | ||
| US202163286691P | 2021-12-07 | 2021-12-07 | |
| US63/286,691 | 2021-12-07 | ||
| PCT/US2022/027763 WO2022235859A1 (en) | 2021-05-07 | 2022-05-05 | Cycloalkyl 3-oxopiperazine carboxamides and cycloheteroalkyl 3-oxopiperazine carboxamides as nav1.8 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117881664A true CN117881664A (zh) | 2024-04-12 |
Family
ID=81927873
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202280048071.1A Pending CN117881664A (zh) | 2021-05-07 | 2022-05-05 | 作为nav1.8抑制剂的环烷基3-氧代哌嗪甲酰胺和环杂烷基3-氧代哌嗪甲酰胺 |
Country Status (21)
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2023013147A (es) * | 2021-05-07 | 2023-11-28 | Merck Sharp & Dohme Llc | Aril 3-oxopiperazin carboxamidas y heteroaril 3-oxopiperazin carboxamidas como inhibidores de nav1.8. |
| JP2025513455A (ja) | 2022-04-22 | 2025-04-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | 疼痛の治療のためのヘテロアリール化合物 |
| IL316422A (en) | 2022-04-22 | 2024-12-01 | Vertex Pharma | Heteroaryl compounds for pain treatment |
| AU2023255558A1 (en) | 2022-04-22 | 2024-10-31 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| AU2023257313A1 (en) | 2022-04-22 | 2024-10-31 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| KR20250120351A (ko) | 2022-12-06 | 2025-08-08 | 버텍스 파마슈티칼스 인코포레이티드 | 나트륨 채널의 치환된 테트라하이드로푸란 조절제의 합성을 위한 방법 |
| WO2025085564A1 (en) * | 2023-10-16 | 2025-04-24 | Kronos Bio, Inc. | Lysine acetyltransferase inhibitors |
| CN117645533B (zh) * | 2023-10-20 | 2024-10-11 | 泰州精英化成医药科技有限公司 | 一种4-(三氟甲基)环己酮的合成方法 |
| TW202535867A (zh) | 2023-10-23 | 2025-09-16 | 美商維泰克斯製藥公司 | 用於治療疼痛之鈉通道調節劑及其固體形式的製備方法 |
| KR20260116140A (ko) | 2023-10-23 | 2026-07-28 | 버텍스 파마슈티칼스 인코포레이티드 | 통증 치료를 위한 헤테로아릴 화합물 |
| KR20260116141A (ko) | 2023-10-23 | 2026-07-28 | 버텍스 파마슈티칼스 인코포레이티드 | 통증 치료용 화합물 및 이의 고체 형태의 제조방법 |
| KR20260118418A (ko) | 2023-10-23 | 2026-07-30 | 버텍스 파마슈티칼스 인코포레이티드 | 통증 치료를 위한 헤테로아릴 화합물 |
| CN117567323A (zh) * | 2023-10-30 | 2024-02-20 | 湖北泰盛化工有限公司 | 一种(s)-4-氯-2-((甲氧基羰基)氨基)丁酸乙酯的制备方法 |
| AU2024393245A1 (en) | 2023-12-07 | 2026-06-18 | Vertex Pharmaceuticals Incorporated | Dosing regimens and formulations of suzetrigine for use in the treatment of acute and chronic pain |
| TW202606663A (zh) | 2024-06-28 | 2026-02-16 | 美商維泰克斯製藥公司 | 用於治療疼痛之雜芳基化合物 |
| LU605402B1 (en) | 2024-07-11 | 2026-07-14 | Sea4Us Biotecnologia E Recursos Marinhos Sa | Oxazolidone-derived compounds and their use in the treatment of chronic and acute pain |
| WO2026030525A1 (en) | 2024-07-31 | 2026-02-05 | Vertex Pharmaceuticals Incorporated | Zilvetrigine dosage forms and dosing regimens for treating pain |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101035783A (zh) * | 2004-08-30 | 2007-09-12 | 神经医药品有限公司 | 作为钙通道阻断剂的脲衍生物 |
| WO2011026240A1 (en) * | 2009-09-04 | 2011-03-10 | Zalicus Pharmaceuticals Ltd. | Oxopiperazine derivatives for the treatment of pain and epilepsy |
| WO2020092187A1 (en) * | 2018-11-02 | 2020-05-07 | Merck Sharp & Dohme Corp. | 2-amino-n-phenyl-nicotinamides as nav1.8 inhibitors |
| WO2020092667A1 (en) * | 2018-11-02 | 2020-05-07 | Merck Sharp & Dohme Corp. | 2-amino-n-heteroaryl-nicotinamides as nav1.8 inhibitors |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS52122392A (en) * | 1976-04-07 | 1977-10-14 | Sangyo Kagaku Kenkyu Kyokai | Novel antibacterials |
| CA2550257A1 (en) | 2003-12-18 | 2005-07-07 | Cv Therapeutics, Inc. | 1-akan-2-ol substituted piperazine and piperidine compounds |
| EP2212290B1 (en) | 2007-10-11 | 2014-12-03 | Vertex Pharmaceuticals Incorporated | Aryl amides useful as inhibitors of voltage-gated sodium channels |
| MX2010003864A (es) | 2007-10-11 | 2010-06-01 | Vertex Pharma | Amidas utiles como inhibidores de canales de sodio dependientes de voltaje. |
| CA2701946A1 (en) | 2007-10-11 | 2009-04-16 | Vertex Pharmaceuticals Incorporated | Heteroaryl amides useful as inhibitors of voltage-gated sodium channels |
| US8889863B2 (en) | 2010-07-16 | 2014-11-18 | Vanderbilt University | Stereoselective methods, catalysts and intermediates for the synthesis of (−)-Nutlin-3 and related compounds |
| KR102226587B1 (ko) | 2013-01-31 | 2021-03-11 | 버텍스 파마슈티칼스 인코포레이티드 | 나트륨 채널의 조절제로서의 퀴놀린 및 퀴나졸린 아미드 |
| BR112015018284B1 (pt) | 2013-01-31 | 2023-03-07 | Vertex Pharmaceuticals Incorporated | Amidas como moduladores de canais de sódio, seus usos, e composição farmacêutica |
| CN105026373B (zh) | 2013-01-31 | 2018-03-30 | 沃泰克斯药物股份有限公司 | 作为钠通道调节剂的吡啶酮酰胺 |
| JP6337109B2 (ja) | 2013-07-19 | 2018-06-06 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | ナトリウムチャネルの調節剤としてのスルホンアミド |
| SG11201604477SA (en) | 2013-12-13 | 2016-07-28 | Vertex Pharma | Prodrugs of pyridone amides useful as modulators of sodium channels |
| JP2017114764A (ja) | 2014-04-25 | 2017-06-29 | 武田薬品工業株式会社 | 片頭痛治療剤 |
| WO2015184383A1 (en) | 2014-05-29 | 2015-12-03 | St. Jude Children's Research Hospital | Aryl-substituted imidazoles and methods of making and using same |
| KR101844984B1 (ko) | 2016-05-31 | 2018-04-03 | 한림대학교 산학협력단 | 5원 헤테로사이클릭 유도체, 이의 제조방법 및 이를 포함하는 약제학적 조성물 |
| KR102714561B1 (ko) | 2017-05-16 | 2024-10-10 | 버텍스 파마슈티칼스 인코포레이티드 | 나트륨 채널의 조절제로서의 중수소화 피리돈 아미드 및 이의 프로드럭 |
| AU2018300150A1 (en) | 2017-07-11 | 2020-01-30 | Vertex Pharmaceuticals Incorporated | Carboxamides as modulators of sodium channels |
| US11419874B2 (en) | 2017-11-23 | 2022-08-23 | Oslo University Hospital Hf | Treatment of tachycardia |
| US12173018B2 (en) | 2018-05-25 | 2024-12-24 | VenatoRx Pharmaceuticals, Inc. | Penicillin-binding protein inhibitors |
| WO2021108023A1 (en) | 2019-11-26 | 2021-06-03 | VenatoRx Pharmaceuticals, Inc. | Penicillin-binding protein inhibitors |
| US11802122B2 (en) * | 2020-06-17 | 2023-10-31 | Merck Sharp & Dohme Llc | 2-oxoimidazolidine-4-carboxamides as NAv1.8 inhibitors |
| CN115697327A (zh) * | 2020-06-17 | 2023-02-03 | 默沙东有限责任公司 | 作为nav1.8抑制剂的5-氧代-吡咯烷-3-甲酰胺 |
-
2022
- 2022-05-05 EP EP22727539.3A patent/EP4334293A1/en active Pending
- 2022-05-05 TW TW111116959A patent/TWI827037B/zh active
- 2022-05-05 MX MX2023013146A patent/MX2023013146A/es unknown
- 2022-05-05 GE GEAP202216407A patent/GEP20257795B/en unknown
- 2022-05-05 US US17/737,070 patent/US20220380338A1/en active Pending
- 2022-05-05 JP JP2023567928A patent/JP7522943B2/ja active Active
- 2022-05-05 WO PCT/US2022/027763 patent/WO2022235859A1/en not_active Ceased
- 2022-05-05 CN CN202280048071.1A patent/CN117881664A/zh active Pending
- 2022-05-05 IL IL308215A patent/IL308215A/en unknown
- 2022-05-05 GE GEAP202416407A patent/GEAP202416407A/en unknown
- 2022-05-05 CA CA3217565A patent/CA3217565A1/en active Pending
- 2022-05-05 AR ARP220101186A patent/AR125786A1/es unknown
- 2022-05-05 CR CR20230519A patent/CR20230519A/es unknown
- 2022-05-05 AU AU2022270115A patent/AU2022270115B2/en active Active
- 2022-05-05 KR KR1020237042098A patent/KR102987078B1/ko active Active
- 2022-05-05 BR BR112023023239A patent/BR112023023239A2/pt unknown
- 2022-05-05 PE PE2023003016A patent/PE20250021A1/es unknown
-
2023
- 2023-11-01 DO DO2023000242A patent/DOP2023000242A/es unknown
- 2023-11-06 JO JOJO/P/2023/0284A patent/JOP20230284A1/ar unknown
- 2023-11-06 CL CL2023003295A patent/CL2023003295A1/es unknown
- 2023-11-06 EC ECSENADI202383881A patent/ECSP23083881A/es unknown
- 2023-11-07 CO CONC2023/0015096A patent/CO2023015096A2/es unknown
-
2024
- 2024-01-05 JP JP2024000646A patent/JP2024038267A/ja active Pending
-
2025
- 2025-12-18 JP JP2025264265A patent/JP2026048891A/ja active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101035783A (zh) * | 2004-08-30 | 2007-09-12 | 神经医药品有限公司 | 作为钙通道阻断剂的脲衍生物 |
| WO2011026240A1 (en) * | 2009-09-04 | 2011-03-10 | Zalicus Pharmaceuticals Ltd. | Oxopiperazine derivatives for the treatment of pain and epilepsy |
| WO2020092187A1 (en) * | 2018-11-02 | 2020-05-07 | Merck Sharp & Dohme Corp. | 2-amino-n-phenyl-nicotinamides as nav1.8 inhibitors |
| WO2020092667A1 (en) * | 2018-11-02 | 2020-05-07 | Merck Sharp & Dohme Corp. | 2-amino-n-heteroaryl-nicotinamides as nav1.8 inhibitors |
Also Published As
| Publication number | Publication date |
|---|---|
| GEP20257795B (en) | 2025-09-25 |
| TWI827037B (zh) | 2023-12-21 |
| EP4334293A1 (en) | 2024-03-13 |
| JP2024038267A (ja) | 2024-03-19 |
| ECSP23083881A (es) | 2023-12-29 |
| DOP2023000242A (es) | 2023-12-15 |
| AU2022270115A1 (en) | 2023-11-16 |
| WO2022235859A1 (en) | 2022-11-10 |
| IL308215A (en) | 2024-01-01 |
| JP2024515895A (ja) | 2024-04-10 |
| MX2023013146A (es) | 2023-11-28 |
| AR125786A1 (es) | 2023-08-16 |
| KR102987078B1 (ko) | 2026-07-07 |
| CA3217565A1 (en) | 2022-11-10 |
| CR20230519A (es) | 2024-01-19 |
| TW202308999A (zh) | 2023-03-01 |
| CL2023003295A1 (es) | 2024-07-12 |
| CO2023015096A2 (es) | 2023-11-20 |
| GEAP202416407A (en) | 2024-03-25 |
| KR20240005878A (ko) | 2024-01-12 |
| JOP20230284A1 (ar) | 2023-11-06 |
| JP7522943B2 (ja) | 2024-07-25 |
| BR112023023239A2 (pt) | 2024-01-23 |
| JP2026048891A (ja) | 2026-03-17 |
| PE20250021A1 (es) | 2025-01-07 |
| US20220380338A1 (en) | 2022-12-01 |
| AU2022270115B2 (en) | 2025-08-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7522943B2 (ja) | Ｎａｖ１．８阻害薬としてのシクロアルキル ３－オキソピペラジンカルボキサミド類及びシクロヘテロアルキル ３－オキソピペラジンカルボキサミド類 | |
| JP7575518B2 (ja) | Ｎａｖ１．８阻害剤としての２－オキソイミダゾリジン－４－カルボキサミド | |
| CN116056697A (zh) | 作为nav1.8抑制剂的2-氧代-噁唑烷-5-甲酰胺 | |
| JP7846132B2 (ja) | Ｎａｖ１．８阻害薬としてのアリール ３－オキソピペラジンカルボキサミド類及びヘテロアリール ３－オキソピペラジンカルボキサミド類 | |
| CN115697327A (zh) | 作为nav1.8抑制剂的5-氧代-吡咯烷-3-甲酰胺 | |
| EA051500B1 (ru) | ЦИКЛОАЛКИЛ 3-ОКСОПИПЕРАЗИНКАРБОКСАМИДЫ И ЦИКЛОГЕТЕРОАЛКИЛ 3-ОКСОПИПЕРАЗИНКАРБОКСАМИДЫ В КАЧЕСТВЕ ИНГИБИТОРОВ NaV1.8 | |
| HK40108385A (en) | Cycloalkyl 3-oxopiperazine carboxamides and cycloheteroalkyl 3-oxopiperazine carboxamides as nav1.8 inhibitors | |
| EA048797B1 (ru) | 2-оксоимидазолидин-5-карбоксамиды в качестве ингибиторов nav1.8 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40108385 Country of ref document: HK |